File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ovarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor

TitleOvarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor
Authors
Keywordschoriocarcinoma
clear cell carcinoma
neoadjuvant chemotherapy
nongestatational choriocarcinoma
ovarian carcinoma
Issue Date2010
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.com
Citation
International Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545 How to Cite?
Abstract
Ovarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. © 2010 International Society of Gynecological Pathologists.
Persistent Identifierhttp://hdl.handle.net/10722/135675
ISSN
2013 Impact Factor: 1.631
ISI Accession Number ID
References

 

Author Affiliations
  1. The University of Hong Kong
DC FieldValueLanguage
dc.contributor.authorHu, YJen_HK
dc.contributor.authorIp, PPCen_HK
dc.contributor.authorChan, KKLen_HK
dc.contributor.authorTam, KFen_HK
dc.contributor.authorNgan, HYSen_HK
dc.date.accessioned2011-07-27T01:39:12Z-
dc.date.available2011-07-27T01:39:12Z-
dc.date.issued2010en_HK
dc.identifier.citationInternational Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545en_HK
dc.identifier.issn0277-1691en_HK
dc.identifier.urihttp://hdl.handle.net/10722/135675-
dc.description.abstractOvarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. © 2010 International Society of Gynecological Pathologists.en_HK
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.comen_HK
dc.relation.ispartofInternational Journal of Gynecological Pathologyen_HK
dc.subjectchoriocarcinomaen_HK
dc.subjectclear cell carcinomaen_HK
dc.subjectneoadjuvant chemotherapyen_HK
dc.subjectnongestatational choriocarcinomaen_HK
dc.subjectovarian carcinomaen_HK
dc.subject.meshAdenocarcinoma, Clear Cell - pathology - therapy-
dc.subject.meshAntineoplastic Agents - therapeutic use-
dc.subject.meshChoriocarcinoma, Non-gestational - pathology - therapy-
dc.subject.meshGynecologic Surgical Procedures-
dc.subject.meshOvarian Neoplasms - pathology - therapy-
dc.titleOvarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumoren_HK
dc.typeArticleen_HK
dc.identifier.emailChan, KKL:kklchan@hkucc.hku.hken_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityChan, KKL=rp00499en_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/PGP.0b013e3181e7cc66en_HK
dc.identifier.pmid20881859en_HK
dc.identifier.scopuseid_2-s2.0-78149285342en_HK
dc.identifier.hkuros186767en_US
dc.identifier.hkuros188236en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78149285342&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume29en_HK
dc.identifier.issue6en_HK
dc.identifier.spage539en_HK
dc.identifier.epage545en_HK
dc.identifier.isiWOS:000283264400006-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHu, YJ=37031077400en_HK
dc.identifier.scopusauthoridIp, PPC=7003622683en_HK
dc.identifier.scopusauthoridChan, KKL=8655666700en_HK
dc.identifier.scopusauthoridTam, KF=7201692816en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats